dynaCERT Graduates to OTCQB in the USA
TORONTO--(BUSINESS WIRE)-- dynaCERT Inc. (TSX: DYA) (OTCQB: DYFSF) (FRA: DMJ) (" dynaCERT" or the "Company") is pleased to announce that it has qualified for graduation to the OTCQB and its common shares will continue trading in the United States today (June 2, 2025) under the symbol DYFSF. The OTCQB Venture Market in the United States is operated by the OTC Markets Group Inc.
dynaCERT 's common shares continue to be listed on the Toronto Stock Exchange, Canada's premier senior exchange, under the symbol DYA, and on the Frankfurt Stock Exchange in Europe, under the symbol DMJ as well as trading globally on numerous other platforms.
Benefits of Trading on the OTCQB
Graduating to the OTCQB, the OTC Bulletin Board, means that dynaCERT 's common shares start trading on the middle-tier OTC market, which is also known as the "Venture Market". This marks a significant step for the Company, offering dynaCERT more liquidity, visibility and potentially a larger investor base. This graduation also provides a more seamless trading experience for investors in the United States.
Real-Time Level 2 Quotes
Investors in the USA can find more information about dynaCERT and its Real-Time Level 2 Quotes on the OTCQB at: https://www.otcmarkets.com/stock/DYFSF/quote
Jim Payne, Chairman and CEO of dynaCERT, stated, ' dynaCERT thanks the OTC for graduating the Company to OTCQB. As a global leader of hydrogen-on-demand technology, we offer our full line of proprietary technology also to the USA market. Our unique HydraGEN™ models are designed to reduce fuel consumption and GHG emissions in diesel engines in many industries including in logistics, transportation, mining, oil & gas and construction. By backing our initiatives, US-based businesses support clean energy solutions. We, at dynaCERT, are proud to be part of this momentum.'
About dynaCERT Inc.
dynaCERT Inc. manufactures and distributes Carbon Emission Reduction Technology along with its proprietary HydraLytica™ Telematics, a means of monitoring fuel consumption and calculating GHG emissions savings designed for the tracking of possible future Carbon Credits for use with internal combustion engines. As part of the growing global hydrogen economy, our patented technology creates hydrogen and oxygen on-demand through a unique electrolysis system and supplies these gases through the air intake to enhance combustion, which has shown to lower carbon emissions and improve fuel efficiency. Our technology is designed for use with many types and sizes of diesel engines used in on-road vehicles, reefer trailers, off-road construction, power generation, mining and forestry equipment. Website: www. dynaCERT.com.
This press release of dynaCERT Inc. contains statements that constitute "forward-looking statements". Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause dynaCERT's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. In particular, information relating to the OTC, the OTCQB and their platforms cannot be independently verified. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Actual results may vary from the forward-looking information in this news release due to certain material risk factors.
Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance of achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; the uncertainty of the emerging hydrogen economy; including the hydrogen economy moving at a pace not anticipated; our ability to secure and maintain strategic relationships and distribution agreements; and the other risk factors disclosed under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of the release.
On Behalf of the Board
Murray James Payne,
Chairman & CEO
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
17 minutes ago
- Business Upturn
HistoSonics and Cambridge University Unveil Europe's First Edison™ Histotripsy System Powered by Li Ka Shing Foundation Gift
MINNEAPOLIS, United States: HistoSonics, the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, announced today that Addenbrookes Hospital of Cambridge University Hospital Foundation and Trust will be the first site in the United Kingdom and European continent to offer histotripsy to both NHS and private patients. This was made possible through a generous donation by the Li Ka Shing Foundation (LKSF) as well as the expedited limited market access granted by the MHRA in April 2025. This press release features multimedia. View the full release here: The milestone marks HistoSonics' official entry into the UK and European market. HistoSonics won a coveted place in the Innovative Device Access Pathway pilot in 2024 and through this program, in partnership with the DHSC, MHRA, NIHR, NHSE, and NICE expedited access to patients. HistoSonics will continue to work with UK healthcare stakeholders on our aligned goal of urgently expanding access for all NHS patients. The Li Ka Shing Foundation, established in 1980 by Hong Kong philanthropist Sir Ka-shing Li, has contributed nearly US$4 billion to advancing education, medical research and services, and poverty alleviation across the USA, UK, Canada, and Asia. Recognizing the transformative potential of technological innovation in healthcare, the Foundation's latest gift to the University of Cambridge will build upon its previous donations of five Edison systems with three to Hong Kong, one to Singapore, and one recently to Stanford University. This new gift not only heralds the introduction of the first Edison system in the UK and Europe but also celebrates the enduring partnership between the Li Ka Shing Foundation and Cambridge in their collaborative efforts to fight cancer. By supporting cutting-edge medical technologies that can deliver low cost and highly efficient solutions, the Foundation hopes to enhance patient access with improved healthcare around the world. 'This donation is an historic milestone that brings non-invasive treatment of liver tumors using histotripsy to the UK,' said Mike Blue, President and CEO, HistoSonics. 'We are grateful to the Li Ka Shing Foundation for their visionary support. With Addenbrookes as our first NHS hospital site under UCNA, we are laying the foundation for future expansion into innovation driven hospitals across the UK.' The Edison System, which received FDA De Novo clearance in October 2023, uses non-invasive therapeutic focused ultrasound energy to mechanically destroy and liquefy targeted tissue and tumors without the invasiveness or toxicity of traditional procedures, reducing the risks of bleeding, infection, and damage to surrounding non-targeted tissue. HistoSonics' initial FDA clearance is for the destruction of liver tumors, with ongoing studies focusing on kidney tumors (HOPE4KIDNEY Trial NCT05820087) and pancreas tumors (GANNON Trial NCT06282809). Professor Deborah Prentice, Vice-Chancellor of the University of Cambridge, said: 'We are very fortunate that through the generosity of Sir Ka-shing Li, Addenbrooke's Hospital in Cambridge will be able to use cutting-edge histotripsy technology to improve outcomes for NHS patients. It is technology such as this that allows Cambridge to remain at the forefront of understanding and treating tumors, a position we aim to strengthen further with Cambridge Cancer Research Hospital.' With installations soon to be in five countries including the US, UK, Hong Kong, Singapore and the United Arab Emirates, HistoSonics is actively expanding access to its histotripsy platform and is working closely with clinical leaders, national health systems, and philanthropic partners to accelerate global adoption of histotripsy as a new category of health care. HistoSonics is also pursuing broader UK and European market access via CE marking. United Kingdom Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumours, including the partial or complete destruction of unresectable liver tumours via histotripsy. This includes malignancy linked to primary liver cancer and cases of metastatic disease in the liver. The device should only be used by people who have completed training performed by HistoSonics Inc., and its use guided by the clinical judgement of an appropriately trained physician. Users must read this user guide to understand the warnings, precautions, and clinical trial summary, including reported adverse events. The Edison System has not been evaluated for the treatment of any specific disease, including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumour progression, 5-year survival or overall survival). United States Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by physicians who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions, and a summary of clinical trial results, including reported adverse events. About HistoSonics HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, and others. HistoSonics has offices in Ann Arbor, Michigan and Minneapolis, MN. For more information on the Edison Histotripsy System please visit: For patient-related information please visit: View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Yahoo
20 minutes ago
- Yahoo
Rolls-Royce to build Britain's first mini nuclear reactors
Rolls-Royce will build the country's first mini nuclear power plants as part of a multibillion-pound effort to make Britain a world leader in the technology. The Derby-based engineering giant was on Tuesday confirmed as the sole winner of a design competition, beating rivals GE-Hitachi and Holtec International following a two-year selection process. It will now work with the Government on a programme to initially build three the first small modular reactors (SMRs) by the 2030s, with £2.5bn of funding pledged through 2029 and billions more expected beyond that once construction begins. Ministers said the decision showed they were 'backing Britain', with the majority of the supply chain expected to be based domestically. As a 'preferred' bidder, Rolls will now hold talks to negotiate a final contract with the Government. A location has yet to be announced but sites including Wylfa, in Anglesey, and Oldbury-on-Severn, in Gloucestershire, are among those being considered. Ed Miliband, the Energy Secretary, said the scheme would boost energy security and create thousands of jobs, as part of a new 'golden age of nuclear' that has also seen the Government pledge £14bn of new funding to the construction of Sizewell C. Rachel Reeves, the Chancellor, added: 'The UK is back where it belongs, taking the lead in the technologies of tomorrow with Rolls-Royce SMR as the preferred partner for this journey. 'We're backing Britain with Great British Energy - Nuclear's ambition to ensure 70pc of supply chain products are British built, delivering our plan for change through more jobs and putting more money in people's pockets.' SMRs would in theory be faster to build than larger nuclear plants, such as Hinkley Point C and Sizewell C, and come with smaller price tags – although they remain unproven commercially. Tuesday's announcement also confirmed cutbacks to the SMR programme, which The Telegraph previously revealed were being considered. The Government had earlier suggested that two or as many as three SMR manufacturers would be chosen to take designs forward, with nuclear industry insiders saying this would boost competition and ensure a 'backup' was available should the main winner run into trouble. But with the Treasury under pressure to find billions of pounds for other priorities such as the NHS and police forces, the scale of the programme now appears to have been trimmed back. Ministers also confirmed that Great British Nuclear, the quango set up to manage the new mini-nuclear programme, would be absorbed into Mr Miliband's publicly owned Great British Energy. Tufan Erginbilgic, chief executive of Rolls-Royce, said: 'This is a very significant milestone for our business. 'It is a vote of confidence in our unique nuclear capabilities, which will be recognised by governments around the world.' Rolls has also been selected by the Czech government to build some of Europe's first SMRs in a joint venture with state energy firm CEZ. The decision brings to a close a process that was first promised by George Osborne, the former chancellor, in 2015 but did not begin until 2023 under the previous Conservative government. Rolls was widely viewed as the frontrunner in the process and had already been awarded £210m of taxpayer support in 2021 towards the development costs of its SMR technology. But in the past year, ministers have faced calls from Rolls boss Erginbilgic to push forward more quickly to ensure Britain retains 'first mover advantage'. The global SMR market is projected to be worth up to £500bn by 2050, according to the International Energy Agency. Rolls is vying against companies including Westinghouse and GE-Hitachi to secure customers and set up supply chains. The company has long supplied the pressurised water reactors that power Royal Navy submarines but has more recently sought to develop SMRs and even smaller 'micro reactors' for commercial use as well. Its SMRs would be constructed from 'modules' that are built in factories and then transported to sites for assembly. The idea is meant to ensure that the plants can be produced efficiently at scale and more quickly than larger nuclear projects. As part of the SMR competition, the Government asked companies to explain how they would bring down costs over time. In the longer run, it is also hoped that the smaller price tags of SMRs will ensure they are more attractive to private investors, which have long viewed bigger plants as too expensive and risky to back without government support. Major technology companies including Google, Amazon and Facebook owner Meta are investing in potential SMR technologies, amid suggestions they could eventually be used to supply power-hungry data centres needed to develop artificial intelligence. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Yahoo
25 minutes ago
- Yahoo
US Telecoms Face Capex Decline Amid Economic Challenges: A Review of Key Operators Including AT&T, Verizon, Charter, Comcast, T-Mobile (DT), Lumen, Frontier, and More
The brief analyzes the US telecom capital expenditure trends, using data from key operators like AT&T and Verizon. In 2024, US telco capex was $80.5 billion, but with concerns over inflation and recession, spending is expected to decline. Telcos are leveraging AI for operational efficiency, amid economic and policy uncertainties. Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "US Telco Capex Fading as AI Giants Take Center Stage" report has been added to offering. This brief examines the near-term outlook for telecom capital expenditures (capex) in the US, based on the 1Q25 earnings of key operators, including AT&T, Verizon, Charter, Comcast, T-Mobile (DT), Lumen, Frontier, and more. It analyzes how current spending patterns compare with previous forecasts, highlights the main forces shaping investment decisions, explores implications for vendors, and discusses trends in emerging areas such as AI, large language models (LLMs), and data centers. The US market closed 2024 with $80.5 billion in telco capex and $505.2 billion in revenues, representing 27% and 28% of global industry totals, respectively. The USA's capex to revenue ratio, or capital intensity, was in the 17-18% range in 2022-23. That was well above historic levels. The ratio started to moderate in 2024. For full-year 2024, capital intensity was 15.9%. Based upon 1Q25 earnings calls and other datapoints, that will fall further. US telcos are looking to monetize recent investments, and more focused on conserving capital and cutting costs. Economic and policy uncertainty continues to be high, with inflation and recession fears stemming from the presidentially contrived trade emergency. As telcos conserve capex, they must see irony in the massive investment bubble in the data center market. Telcos are struggling to attract the same investor interest. However, telcos are finding other ways to benefit from AI in the US. They aren't positioned well to ride the GenAI wave, but they are deploying AI-based technologies to deliver operational efficiency. For instance: AT&T: using AI to improve call center automation, software development, and digital acquisition. The company says that investment in automation is helping offset labor costs and drive self-service efficiency across sales and support channels. Verizon: integrating AI into customer care and network ops; use cases include predictive maintenance, customer service automation, and internal process efficiencies. Comcast: AI is deployed across billing automation, network troubleshooting, and customer service, reducing truck rolls and call center loads. Machine learning models are used to predict customer churn and drive targeted promotions. Charter: has invested in AI for years, focused on frontline efficiency and self-service; it is reducing repair calls and truck rolls. Internal tools are used to optimize operations, enhance agent support, and reduce OPEX. DT/T-Mobile: AI is integral to DT's digital transformation, aiming at €800 million in group cost savings by 2027. AI is used to optimize fiber rollouts, automate customer service (e.g., chatbots solving 50% of issues without humans), and remotely manage 75% of routers. DT says that AI supports operations across service, coding, sales, and mobile RAN monitoring. Lumen: Lumen is positioning itself as a backbone provider for the AI economy. Lumen Digital platform uses AI for automation and real-time network control. Over the next few quarters, US telcos will remain tightly constrained on capex. Weaker economic growth will hit revenues. Rising government debt and tariffs will cause inflation to spike. Fewer international visitors to the US, less foreign investment, both lead to weaker demand. Tariffs may also cause shortages or high costs in certain component parts used in building networks. Labor costs will rise, as the surge in investment from an adjacent sector (data centers) will make it harder for telcos to keep their staff. But telcos have been wrestling with such issues for years, and they will survive this as well. Key Topics Covered: Summary Market Background - USA 1Q25 results AT&T Verizon Comcast Charter Communications T-Mobile (DT) Frontier Communications Lumen Technologies (ex-CenturyLink) Dish Network (EchoStar) List of Figures Capex forecast for US telco market and recent changes Major capex spenders in US telco, CY24 versus 4Q24 ($M and % total) Summary of US telcos' 2025 capex focus & forecast AT&T's total corporate capex, capital intensity, and share of global capex Verizon's total corporate capex, capital intensity, and share of global capex Comcast's total corporate capex, capital intensity, and share of global capex Charter Communications' total corporate capex, capital intensity, and share of global capex T-Mobile total corporate capex, capital intensity, and share of global capex Frontier capex, capital intensity, and share of global capex Lumen capex, capital intensity, and share of global capex Dish Network capex, capital intensity, and share of global capex For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
